ondansetron and rolapitant

ondansetron has been researched along with rolapitant in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y	1
Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L	1
Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S	1

Reviews

1 review(s) available for ondansetron and rolapitant

Article	Year
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget, 2016, Apr-26, Volume: 7, Issue:17 Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting	2016

Article

Year

Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.

Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting

2016

Trials

2 trial(s) available for ondansetron and rolapitant

Article	Year
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Spiro Compounds; Vomiting; Young Adult	2015
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. European journal of cancer (Oxford, England : 1990), 2016, Volume: 57 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Randomized Controlled Trials as Topic; Retreatment; Serotonin 5-HT3 Receptor Antagonists; Spiro Compounds; Treatment Outcome; Vomiting; Young Adult	2016

Article

Year

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:11

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Spiro Compounds; Vomiting; Young Adult

2015

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.

European journal of cancer (Oxford, England : 1990), 2016, Volume: 57

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Randomized Controlled Trials as Topic; Retreatment; Serotonin 5-HT3 Receptor Antagonists; Spiro Compounds; Treatment Outcome; Vomiting; Young Adult

2016